New frontiers in anti-cancer drug testing: The need for a relevant In vitro testing model.

Area of Science:

• Oncology
• Biotechnology
• Pharmacology

Background:

• In vitro drug development relies heavily on cell cultures for efficacy and toxicity assessments.
• Traditional 2D monolayer cell cultures lack the in vivo microenvironment complexity, limiting their predictive power.
• Ethical concerns and limitations exist with preclinical animal testing models.

Purpose of the Study:

• To compare the efficacy and toxicity of anti-cancer drugs using traditional monolayer cell cultures versus 3D spheroid models.
• To evaluate the advantages and limitations of each in vitro model in preclinical drug development.
• To highlight spheroid models as a more physiologically relevant alternative to monolayer cultures.

Main Methods:

• Review of anti-cancer drugs (5-Fluorouracil, Tirapazamine, Cisplatin, Resveratrol, Irinotecan, Doxorubicin) tested in both 2D and 3D models.
• Analysis of various analytical methods used to assess drug efficacy and toxicity.
• Comparison of results obtained from monolayer cultures and spheroid models.

Main Results:

• Spheroid models provide a more accurate representation of the in vivo tumor microenvironment compared to 2D cultures.
• Differences in drug efficacy and toxicity profiles were observed between the two model systems.
• 3D spheroid models offer enhanced insights into cell-to-cell and cell-to-matrix interactions relevant to drug response.

Conclusions:

• Spheroid models are superior to traditional monolayer cultures for evaluating anti-cancer drug efficacy and toxicity due to their 3D structure.
• The use of spheroid models can improve the predictive accuracy of preclinical drug development and potentially reduce reliance on animal models.
• Further research utilizing 3D spheroid models is recommended for comprehensive anti-cancer drug evaluation.